More about

Psilocybin

News
March 03, 2025
3 min read
Save

Psilocybin may improve mental health of people with cancer

Psilocybin-assisted psychotherapy significantly improved a range of psychiatric symptoms among people with cancer, according to research published in Nature Mental Health.

News
January 13, 2025
3 min read
Save

Psilocybin motivates personality changes among adults with alcohol use disorder

Psilocybin-assisted therapy induced positive personality changes in adults with alcohol use disorder, which may help to improve long-term outcomes by limiting traits that encourage relapse such as impulsiveness, according to study results.

News
September 05, 2024
2 min read
Save

High-dose psilocybin may help treat depressive symptoms, with small effect size

High-dose psilocybin showed the potential to treat depressive symptoms, although the effect size appeared small and comparable to that of escitalopram, according to results of a network meta-analysis published in The BMJ.

News
July 18, 2024
2 min read
Save

Illegal hallucinogens found in mushroom gummies sold at gas stations, smoke shops

Mushroom-containing nootropic gummies sold at gas stations and smoke shops in Virginia contained unlabeled psilocybin and psilocin, according to results of an investigation published in Morbidity and Mortality Weekly Report.

News
June 18, 2024
2 min read
Save

Daytime psilocybin adversely affects REM sleep in those with migraine

SAN DIEGO — Patients with migraine who received daytime psilocybin experienced reduced REM sleep, with effects lasting beyond the day of administration, according to a poster at the American Headache Society Annual Scientific Meeting.

News
May 21, 2024
1 min read
Save

Enveric, MindBio partner to advance psilocin prodrugs for mental health disorders

Enveric Biosciences announced it has signed a nonbinding term sheet to out-license a class of novel psilocin prodrugs to MindBio Therapeutics, an agreement that could yield more than $66 million in sales.

News
March 19, 2024
1 min read
Save

FDA grants breakthrough designation to psilocybin analog for major depressive disorder

The FDA has granted breakthrough therapy designation to Cybin’s CYB003, a proprietary deuterated psilocybin analog in development for treatment of major depressive disorder, according to a company press release.

News
March 05, 2024
1 min read
Save

Positive results announced in phase 2 trial of psilocybin for generalized anxiety disorder

Incannex Healthcare has announced positive topline results from its phase 2 PsiGAD1 clinical trial of psilocybin for generalized anxiety disorder, reporting statistically significant improvement in anxiety scores compared with placebo.

News
January 16, 2024
2 min read
Save

Psilocybin reduces depression severity, improves symptoms in bipolar II disorder

A single, 25 mg dose of synthetic psilocybin along with psychotherapy was safe and effective among individuals with bipolar II disorder depression, supporting further study of psychedelics for these patients, according to research.

News
December 29, 2023
2 min read
Save

Top psych stories of 2023: Physician burnout, ‘transformative’ psychedelics, more

Some of the most-viewed stories on Healio Psychiatry over the past year highlighted the FDA designating an at-home depression treatment as a breakthrough device as well as the transformative power of psychedelics.

View more